EXTON, Pa., March 24, 2021 /PRNewswire/ -- Spherix
recently surveyed 100 US gastroenterologists and followed up with
seven qualitative interviews (including an industry key opinion
leader) in order to assess the current pre-advanced systemic
treatment algorithm for inflammatory bowel disease (IBD), along
with the prospects for several oral, small molecule pipeline
therapies. This new Special Topix™ service was
created in response to the three oral, small molecule therapies
currently in Phase 3 development for the treatment of IBD and the
additional three therapies with Phase 2 clinical data.
Through ongoing research provided in Spherix's core services
offered in IBD, Spherix experts began to notice a possible paradigm
shift in the way gastroenterologists are perceiving upcoming
pipeline agents and how they intend on prescribing to
biologic-naïve patients. The combination of qualitative and
quantitative research included in the Special Topix™
service evaluates, in detail, the current treatment algorithm for
pre-advanced systemic therapies, the decision point at which IBD
patients are switched to biologics, and key physician reactions to
oral, small molecule therapies in development.
Gastroenterologists in the survey reported that their most
common first-line treatments for IBD are aminosalicylates and
systemic corticosteroids, though this varied somewhat between
ulcerative colitis and Crohn's disease patients. Additionally,
respondents reported that they typically make at least two
adjustments (dosing changes) to their first-line selection before
making a change to another treatment option. If these adjustments
didn't provide a response or remission for the patient, a majority
of gastroenterologists indicated they will transition the patient
to a biologic therapy. Usage of specific brands and generics of
immunomodulators, aminosalicylates, and systemic corticosteroids
are also evaluated in the report.
The study results revealed that the transition to biologics can
sometimes be a challenge for gastroenterologists and their
patients. Fear of side effects and concerns about safety are
leading barriers for IBD patients starting biologic therapy.
Insurance coverage and fear of shots/injections/infusion are also
commonly cited barriers for patient conversion to biologics.
Prospects for oral, small molecule therapies currently in
development are also captured in the full report. After assessing
awareness of and familiarity with each of the six oral, small
molecule pipeline assets, physicians were asked to review product
descriptions (based on publicly available clinical information for
each product). The therapies either had at least some Phase 2
clinical data or contained Phase 3 clinical results. These pipeline
therapies included:
- Zeposia - ozanimod (BMS)
- Etrasimod (Arena Pharmaceuticals)
- Rinvoq - upadacitinib (AbbVie)
- Filgotinib (Gilead)
- ABX-464 (Abivax)
- BT-11 (Landos Biopharma)
Qualitative feedback on each pipeline profile, along with an
evaluation of likelihood to prescribe, advantages, limitations, and
ranking of preferred therapies. One-third of gastroenterologists
estimated they are "very likely" to prescribe these pipeline
therapies before biologics, assuming two years of successful
prescribing post-FDA approval. However, nearly all
gastroenterologists qualitatively caveated that pricing and
corresponding insurance coverage will be integral to that paradigm
shift in prescribing.
The ranking exercise for these six profiles revealed
gastroenterologists considered not only clinical factors but also
practical issues, such as the likelihood of good insurance coverage
based on each manufacturer's legacy in that regard. At least three
separate mechanisms of action (MOA) were represented by the
competitive set of these therapies, but no single MOA dominated the
ranking exercise, as physicians expressed an interest in having "a
diverse set of tools in the toolbox."
To supplement the findings in the report included in the
Special Topix™: Pre-Advanced Systemic Therapies in IBD
(US) service, Spherix will continue to monitor
gastroenterologists' awareness and receptivity to these pipeline
therapies in both the US and EU markets via their RealTime
Dynamix™ service offered on a quarterly and semiannual
basis in those areas, respectively.
About Special Topix™
Special Topix™: Pre-Advanced Systemic Therapies in IBD
(US) is an independent service that adds to Spherix's
coverage of the treatment of IBD patients by focusing on the
treatment algorithm prior to the use of biologics. This perspective
is vital as a wave of oral, small molecule pipeline therapies are
poised to potentially leapfrog existing biologic treatment and
become foundational IBD therapies. The assessment of the potential
for each of these oral, small molecule therapies is included in the
analysis of this report.
About Spherix Global Insights
Spherix Global Insights is a hyper-focused market intelligence firm
that leverages our own independent data and expertise to provide
strategic guidance, so biopharma stakeholders make decisions with
confidence. We specialize in select immunology, nephrology, and
neurology markets.
All company, brand or product names in this document are
trademarks of their respective holders.
For more information contact:
Kristen Henn, Business Development
Manager
Email: info@spherixglobalinsights.com
www.spherixglobalinsights.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/upcoming-oral-small-molecule-agents-expected-to-leapfrog-existing-biologic-treatment-and-become-foundational-inflammatory-bowel-disease-therapies-301255063.html
SOURCE Spherix Global Insights